Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

Abstract Background To investigate the potential benefit of cytoreductive radiotherapy (cRT) in metastatic castration-resistant prostate cancer (mCRPC) patients receiving abiraterone. Methods From February 2014 to February 2019, 149 mCRPC patients treated with abiraterone were identified. Patients r...

Full description

Bibliographic Details
Main Authors: Yang Liu, Wen Long, Zitong Zhang, Lixin Mai, Sijuan Huang, Boji Liu, Wufei Cao, Jianhua Wu, Fangjian Zhou, Yonghong Li, Liru He
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Radiation Oncology
Subjects:
Metastatic castration-resistant prostate cancer
Cytoreduction
Radiotherapy
Abiraterone
Online Access:https://doi.org/10.1186/s13014-020-01732-y

Internet

https://doi.org/10.1186/s13014-020-01732-y

Similar Items